| Health / Medical Topics |
gp100 Protein (184V)
A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a valine substitution at position 184. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen. (NCI Thesaurus)
YOU MAY ALSO LIKE
A population of CD4+ and CD8+ T-cells isolated from a cancer patient that have been sensitized in vitro to the melanoma-associated antigen…
A vaccine consisting of synthetic glycoprotein 100 (gp100) melanoma antigen and incomplete Freund's adjuvant (IFA), an emulsifying agent and immune system stimulant,…
A synthetic agent derived from the tumor-associated differentiation antigen gp100 DNA. Gp100 DNA is coated onto microscopic gold beads and used…
A melanoma-associated antigen. When administered in a vaccine formulation, gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against…
A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor…
A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with…
